Second-generation antipsychotics in children: risks and monitoring needs

C Lambert, C Panagiotopoulos, J Davidson… - Canadian Family …, 2018 - cfp.ca
Question A 10-year-old male patient presented to my clinic with irritability associated with
autism spectrum disorder, and previous therapeutic efforts had not been successful …

Use of atypical antipsychotics in children: balancing safety and effectiveness

I Kohlstadt, B Vitiello - American family physician, 2010 - search.proquest.com
Abstract Weight Gain and Metabolic Effects Because neurotransmitters alter central satiety
and appetite mechanisms, weight gain is a common adverse effect of antipsychotic …

Stranded on antipsychotics: role of the pediatric clinician

R Ballard, N Heard-Garris - Clinical pediatrics, 2019 - journals.sagepub.com
1154 Clinical Pediatrics 58 (11-12) also thought to better treat the negative symptoms of
schizophrenia, such as apathy and social withdrawal. Manufacturers of these drugs sought …

[HTML][HTML] Management of adverse effects of second-generation antipsychotics in youth

M Raffin, M Gianitelli, A Consoli, O Bonnot… - … Treatment Options in …, 2014 - Springer
Opinion statement Second-generation antipsychotics (SGAs) have been proven effective in
treating several psychiatric conditions in children and adolescents. These atypical …

Ensuring the safety of children treated with second-generation antipsychotics

R Ronsley, L Chow, K Kuss, J Davidson… - The Science and Ethics …, 2015 - Elsevier
Second-generation antipsychotic (SGA) prescriptions for children have steadily increased
over the past two decades. This is in part due to the perception of a reduction in neurological …

[HTML][HTML] Is it clinically defensible to treat children longer term with second generation antipsychotics?

P Hazell - Expert Opinion on Drug Safety, 2018 - Taylor & Francis
Risperidone was the second most commonly prescribed psychotropic agent to children
aged 3-14 years in Australia in 2012, with antipsychotic drugs as a class making up 11% of …

Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis

P Ellul, R Delorme, S Cortese - CNS drugs, 2018 - Springer
Background Weight gain is a potentially concerning side effect of second-generation
antipsychotics (SGAs). Metformin, a biguanide with antihyperglycemic effects, is used to …

Safer Use of Antipsychotics in Youth (SUAY): should treatment be guided by symptoms?

GA Edelsohn, AR Abright - Journal of the American Academy of …, 2021 - europepmc.org
Child and adolescent psychiatrists have company as they wrestle with clinical decision
making regarding when it is appropriate to prescribe an antipsychotic. Pediatricians face a …

Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth

T Pringsheim, C Panagiotopoulos… - Paediatrics & child …, 2011 - academic.oup.com
BACKGROUND: The use of antipsychotics, especially second-generation antipsychotics
(SGAs), for children with mental health disorders in Canada has increased dramatically over …

Pharmacoepidemiology of Antipsychotic Use in Canadian Children and Adolescents

I Garcia-Ortega, T Pringsheim - The Science and Ethics of Antipsychotic …, 2015 - Elsevier
Over the last decade, the use of second-generation antipsychotics (SGAs) in children and
adolescents has dramatically increased in Canada and worldwide. While there is some …